Ágota Barabássy
Biographic Data
| ID | 7386147 |
|---|---|
| NAME | Ágota Barabássy |
| GIVEN NAMES | Ágota |
| FAMILY NAME | Barabássy |
| SIGNATURE | BARABÁSSY Á |
| AFFILIATIONS | Gedeon Richter (Hungary) |
| VERIFIED | No |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 3 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2020 |
| LATEST PUBLICATION YEAR | 2022 |
| H-INDEX | 0 |
Dosing Cariprazine Within and Beyond Clinical Trials
Although the optimal dosing of an antipsychotic medication is known to be essential in the long-term management of schizophrenia, in case of novel drugs such as cariprazine, determining the right dosing strategy is not that simple. Without decades of experience with a particular compound, evidence regarding dosing and titration comes primarily from double-blind, placebo controlled clinical trials that are not necessarily mirroring the real-life e…
What Is the Minimum Clinically Important Change in Negative Symptoms of Schizophrenia? PANSS Based Post-hoc Analyses of a Phase III Clinical Trial
Applying different methods led to different results, ranging between 7.3 and 18.5% improvement from the baseline for the MCID at its earliest occurrence in patients with predominantly negative symptoms of schizophrenia
Cariprazine Safety in Adolescents and the Elderly
Schizophrenia is a life-long mental disorder, affecting young adolescents to elderly patients. Antipsychotic treatment is indicated for all patients with schizophrenia, including the very young and old as well. Developmental issues in the young and decline in organ functioning in the elderly could influence reactions to the drug, and require different dosing regimens. The aim of the present article was to examine the safety profile and dosing req…
No prominent works on this page.
Cariprazine Safety in Adolescents and the Elderly
Schizophrenia is a life-long mental disorder, affecting young adolescents to elderly patients. Antipsychotic treatment is indicated for all patients with schizophrenia, including the very young and old as well. Developmental issues in the young and decline in organ functioning in the elderly could influence reactions to the drug, and require different dosing regimens. The aim of the present article was to examine the safety profile and dosing req…
Dosing Cariprazine Within and Beyond Clinical Trials
Although the optimal dosing of an antipsychotic medication is known to be essential in the long-term management of schizophrenia, in case of novel drugs such as cariprazine, determining the right dosing strategy is not that simple. Without decades of experience with a particular compound, evidence regarding dosing and titration comes primarily from double-blind, placebo controlled clinical trials that are not necessarily mirroring the real-life e…
What Is the Minimum Clinically Important Change in Negative Symptoms of Schizophrenia? PANSS Based Post-hoc Analyses of a Phase III Clinical Trial
Applying different methods led to different results, ranging between 7.3 and 18.5% improvement from the baseline for the MCID at its earliest occurrence in patients with predominantly negative symptoms of schizophrenia
Medicine (3 works) · Schizophrenia research and treatment (3 works) · Health Systems, Economic Evaluations, Quality of Life (2 works) · Internal Medicine (2 works) · Mental Health Research Topics (2 works) · Psychiatry (2 works) · Psychology (2 works) · Schizophrenia (object-oriented programming (2 works) · Cardiovascular Syncope and Autonomic Disorders (1 work) · Clinical trial (1 work)